Navigation Links
Glenmark Announces Appointment of Mr. Philip Andrew Gioia (Phil) as President North America and Global API Business
Date:12/2/2013

MUMBAI, India, December 2, 2013 /PRNewswire/ --

Glenmark Pharmaceuticals announces the appointment of Mr. Philip Andrew Gioia (Phil) as President North America and Global API business. Phil has taken charge of his responsibilities and will be based at Mahwah, NJ, USA. He will be reporting into the Chairman & Managing Director - Mr. Glenn Saldanha. In this role Phil will be responsible for the Generics and Branded business across North America as also the Global API Sales & Marketing. Phil has over 25 years of experience in the US pharmaceutical industry both in the generics and the branded space.

     (Logo: http://photos.prnewswire.com/prnh/20130626/625083)

On his appointment, Mr. Glenn Saldanha mentions, "We believe that with Phil's rich & diversified experience across the Generics & Branded Pharmaceutical businesses as well as Business Development, brings the necessary skills & acumen to lead and grow the North American operations and the API business of Glenmark." 

Phil joins Glenmark from Bausch & Lomb (acquired by Valeant Pharmaceuticals, August 2013), where his career spanned nearly 5 years most recently as Global Head of Diversified Products and Business Development, Pharmaceuticals.  He worked significantly on expanding Bausch & Lomb's product pipeline. Prior to that, he was Division Head - Pharmaceutical Business Unit, North America. His responsibilities included all aspects of P&L management in addition to overall strategic commercial operations for the brand, generic and OTC divisions.

Preceding Bausch & Lomb, Phil enjoyed 13 years of increased responsibility at Barr Pharmaceuticals, Inc. from 1995 until January 2009 (acquired by Teva Pharmaceuticals). He joined the generic business assuming increasing levels of responsibility, then built Barr's branded business as VP/SVP of Sales which included a 300+ person sales force focused on Women's Health. In 2007, Phil was appointed Senior Vice President (SVP) of the $1.6 billion US Generic Sales & Marketing business where he was involved in the portfolio planning, manufacturing, logistics and supply chain activities.  He led the forecasting group, and was very involved in product selection, planning, and logistics; ensuring the best in class customer service with respect to supply and quality within the trade. Phil began his pharmaceutical career with Lederle Laboratories and Forest Pharmaceuticals in various sales and marketing positions.

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2013). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain].

The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers. Its subsidiary, Glenmark Generics Limited services the requirements of the US and Western Europe generics markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

Issued by: Glenmark Pharmaceuticals Limited

http://www.glenmarkpharma.com


'/>"/>
SOURCE Glenmark Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Glenmark Pharmaceuticals Announces Launch of its Child Health CSR Programme in Kenya
2. Glenmarks Consolidated Revenue Increases by 33.96% to Rs. 13812.59 Million for Q3 FY 12-13
3. Vorsitzender & Managing Director von Glenmark Pharma - Herr Glenn Saldanha - erhielt Preis des Schweizer Botschafters für außergewöhnliche Innovation
4. Glenmarks Consolidated Revenue Increases by 18.9% to Rs. 12551.9 Mn for Q2 FY12-13
5. Endo Health Solutions Announces Receipt of Requisite Consents and Expiration of Consent Solicitations Relating to its 7% Senior Notes Due 2019, 7.00% Senior Notes Due 2020 and 7 1/4% Senior Notes Due 2022
6. Thoratec Announces Presentations At Investor Conferences For December 2013
7. QRxPharma Announces MOXDUO License Deal In Israel
8. Elbit Imaging Announces the Results of the Companys Unsecured Financial Creditors Meeting Approving the General Terms of Agreement to be Entered Into With Bank Hapoalim
9. Net Health Announces New Vice President of Training and Implementation
10. Celsion Corporation Announces Strategic Loan Facility
11. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 2017 West Pharmaceutical Services, Inc. ... injectable drug administration, today announced that it will release ... Thursday, October 26, 2017, and will follow with a ... at 9:00 a.m. Eastern Time. To participate on the ... conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):